Dry Eye

According to a news release, Oculis officials hope to forward product candidates to address areas of significant medical needs, including diabetic macular edema, dry eye disease, and neuro-retina indications such as glaucoma, affecting growing patient populations.

Hear how ophthalmologists and optometrists in the United States are recognizing the importance of this year's awareness day.

Adam Szaronos, President and CEO of Trukera Medical, discusses the recent rebranding of TearLab as well as the launch of the ScoutPro Osmolarity System.

The setting for this year's Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide the opportunity for clinical interaction between faculty and attendees along with the practicality of information.

Those who used both traditional and electronic cigarettes reported severe to very severe ophthalmic symptoms.

At AAO 2022 in Chicago, Illinios, Christopher Starr, MD, presented a talk entitled, "Efficacy of OC-01 (varenicline solution) (VNS) 0.03mg for Treatment of Dry Eye Disease Signs and Symptoms in Subjects With and Without Antidepressant/ Anxiolytic Use: Post-hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials."

During a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Vivian Paraskevi Douglas, MD, DVM, MBA, MSc, detailed a study in which investigators used the extensive data in the American Academy of Ophthalmology IRIS Registry to study the difference between the pediatric and adult populations.

Ophthalmologists should instruct their patients to pay attention to their eye health for the long term.

A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.

Although predefined co-primary study endpoints were not met, AR-15512 demonstrated statistically significant improvements in DED signs, symptoms, and disease-related quality of life.

According to the company, topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieve persistent ocular discomfort in severe dry eye disease.

With a few key steps, surgeons can avert potential refractive surprises, and reduce postoperative dry eye for patients.

Reservoir restoration can re establish the normal anatomy and function of the conjunctiva.

By creating customized packages that incorporate the range of diagnostic and treatment options available, practices can simplify dry eye management and improve patients' outcomes.

Oyster Point Pharma Inc. today announced that the largest Medicare pharmacy benefit manager in the United States will add its varenicline solution nasal spray (Tyrvaya) for the treatment of dry eye on its Medicare Part D formularies, effective September 1.

An independent data monitoring committee recommends continuing study with a sample size target of up to 350 Patients. According to the company, no safety concerns have been identified and topline results are expected during the second quarter of 2023.

ThermaMEDx today announced a partnership with EyeCare Partners to expand EverTears distribution across the network of the national provider of clinically integrated eye care.

Tarsus Pharmaceuticals has enrolled the first patient in a Phase 2a clinical trial studying TP-03 for the treatment of meibomian gland disease in patients diagnosed with Demodex mites.

Behin Barahimi, MD, discusses some current trends in the treatment of dry eye disease. An oculoplastic, orbital and reconstructive surgeon, she is a member of the faculty at Vanderbilt Eye Institute.

Oyster Point Pharma Inc. this week announced the expansion of patient access to varenicline solution (Tyrvaya) nasal spray and provided an update on the commercial performance of the spray in the United States. According to the company, its expanded patient access programs include more eligible patients with dry eye disease.

Cynthia Matossian, MD, FACS, ABES, explains why eye care professionals should oversee the selection and use of artificial tears for patients with dry eye.

According to the company, the study found a positive safety and tolerability profile for aCT1 for treatment of corneal injury.

Kala Pharmaceuticals Inc. announced that it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was first announced in May.

NOV03 is an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.

The organization hopes to increase awareness and education of a condition that affects vision, mental health.

RegeneRx Biopharmaceuticals Inc. said its U.S. joint venture partner and licensee, HLB Therapeutics, will expand its ophthalmic clinical development program with RGN-259 in two indications, neurotrophic keratopathy and dry eye disease.

The treatments typically include application of heat, lid hygiene, and massage of eyelid.

One obvious trend has been that dry eye disease is a concurrent problem for virtually all my patients, and we need to address it for optimum comfort and surgical results.

The Phase 3 registrational study is examining AR-15512, a differentiated, novel product candidate for the treatment of the signs and symptoms of Dry Eye Disease

According to the companies, Kala will receive $60 million in upfront payment, and could be eligible to receive additional sales-based milestone payments.